Amid COVID-19 Pandemic, DreaMed Diabetes Announces Implementation of Its Advisor Pro Software at Top-rated U.S. Children’s Hospital
DreaMed’s AdvisorPro platform for personalized optimization of insulin therapy will be integrated into Texas Children’s Diabetes and Endocrine Care Center systems
TEL AVIV, Israel–(BUSINESS WIRE)–#advisorpro—DreaMed Diabetes Ltd., the developer of the personalized, AI- based diabetes management solution, announces a cooperation with Texas Children’s Hospital by integrating its Advisor Pro software to help diabetes care in children and incorporate a simple remote treatment option.
Diabetes remains a serious concern in the United States, with more than 30 million Americans suffering from the disease－more than 1.2 million of whom suffer from type 1, driven by an estimated 40,000 new type 1 cases every year. In the state of Texas, the prevalence of diabetes increased by 40 percent over the last 11 years, prompting a greater need for improved and more accessible insulin treatment, especially in youth. More recently, the COVID-19 pandemic has relegated people with diabetes to staying isolated from the public sphere, due to their susceptibility to complications from infection, as reported by the Centers for Disease Control and Prevention (CDC). Texas Children’s Diabetes and Endocrine Care Center is one of the institutions leading the charge in the efforts to treat diabetes in the state, and doing so remotely.
Texas Children’s Diabetes and Endocrine Care Center is a leader in research and treatment of children with diabetes. With over 3,000 diabetes cases evaluated annually, it is ranked as one of the nation’s best children’s hospitals by the U.S. News & World Report. In working with DreaMed, Texas Children’s Hospital will assist in providing optimized, frequent care for children across the greater Houston area and beyond.
DreaMed’s Advisor Pro platform provides personalized optimization of insulin therapy management, driven by cloud-based technology utilizing artificial intelligence and algorithms for quick and efficient data analysis. The platform’s purpose is to assist medical professionals in the management of people with diabetes, providing personalized insulin dosage recommendations easily and efficiently for each and every patient. Recommendations are based on analysis of information derived from CGM, glucometers, insulin pumps, and the use of event-oriented data.
“DreaMed is proud to announce its collaboration with Texas Children’s Diabetes and Endocrine Care Center, and play a pivotal role in supporting insulin therapy for children in the state of Texas,” says Eran Atlas, Co-Founder and CEO of DreaMed Diabetes. “DreaMed Diabetes’ mission is always to provide people with diabetes and health care professionals with a reliable, automated decision-support tool that empowers every patient with the best care possible.”
About DreaMed Diabetes
DreaMed Diabetes is a medical device company providing personalized diabetes treatment optimization solutions. The company was established in 2014 and commercialized its first product, GlucoSitter, an artificial pancreas technology which was licensed to Medtronic Diabetes. Ever since, DreaMed Diabetes has been vigorously working on the DreaMed Advisor portfolio, decision support tools in the diabetes management space. DreaMed became the first and only company in the world to receive a CE Mark and FDA clearance for DreaMed Advisor Pro, a decision support system in Type I diabetes patients using data from CGM/SMBG and insulin pumps. The company is continuing to develop the DreaMed Advisor portfolio which will aid all people living with diabetes no matter the insulin therapy or diabetes type and their healthcare professionals to provide personalized insulin therapy. For more information please visit www.dreamed-diabetes.com.
ReBlonde for DreaMed Diabetes